Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus

Aim:  Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of rheumatic diseases 2011-08, Vol.14 (3), p.276-281
Hauptverfasser: BUYUKHATIPOGLU, Hakan, BUYUKASLAN, Hasan, PEHLIVAN, Yavuz, CEYLAN, Nurdan, ULAS, Turgay, TARAKCIOGLU, Mehmet, ONAT, Ahmet M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim:  Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclear. Methods:  In this pilot study, we researched a relatively recently identified, very potent vasoconstrictor peptide, urotensin‐II (U‐II), in SLE patients versus those without RP. In addition to its vasoconstrictor effect, U‐II has been implicated in cardiovascular events and atherosclerosis. Increased frequencies of atherosclerosis and cardiovascular events comprise another issue in SLE patients. To address these effects, we included 15 Raynaud’s (+) and 15 Raynaud’s (−) SLE patients and compared both cohorts against age and sex‐matched controls. Results:  We found significantly elevated U‐II activity in both RP (+) and RP (−) SLE patients, relative to controls (P 
ISSN:1756-1841
1756-185X
DOI:10.1111/j.1756-185X.2011.01597.x